WuXi Biologics (Cayman) Inc. (HKG: 2269)
Hong Kong
· Delayed Price · Currency is HKD
18.02
+0.12 (0.67%)
Oct 10, 2024, 4:08 PM HKT
WuXi Biologics Revenue
WuXi Biologics had revenue of 8.57B CNY in the half year ending June 30, 2024, with 18.98% growth. This brings the company's revenue in the last twelve months to 17.12B, up 3.40% year-over-year. In the year 2023, WuXi Biologics had annual revenue of 17.03B with 11.56% growth.
Revenue (ttm)
17.12B CNY
Revenue Growth
+3.40%
P/S Ratio
4.05
Revenue / Employee
1.34M CNY
Employees
12,740
Market Cap
73.96B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
Dec 31, 2019 | 3.98B | 1.45B | 57.18% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionWuXi Biologics News
- 7 days ago - Chinese biotechs gain as drugmakers targeted in new security bill said to mull divestments - Seeking Alpha
- 7 days ago - WuXi considering selling its Dundalk plant: report - Independent Ireland
- 7 days ago - WuXi AppTec, WuXi Biologics surge in Hong Kong as biotech firms put some operations for sale - South China Morning Post
- 11 days ago - Bullish Chinese investors charge into Hong Kong stocks in stimulus-ignited buying frenzy - South China Morning Post
- 14 days ago - WuXi Biologics: Consider Proposed Legislation And Financial Prospects - Seeking Alpha
- 18 days ago - WuXi Biologics Included in Hang Seng ESG 50 Index - PRNewsWire
- 4 weeks ago - Alibaba, WuXi Biologics lead Hong Kong stock rebound on fund inflows, Fed rate focus - South China Morning Post
- 4 weeks ago - Wuxi AppTec and Wuxi Biologics drop on passage of US bill targeting China biotech firms - South China Morning Post